This feature examines the impact of pharmacologic interventions on the treatment of the critically ill patient — an area of health care that has become increasingly complex. Recent advances in drug therapy for adult ICU patients (including evolving and controversial data) will be reviewed and assessed in terms of clinical, humanistic, and economic outcomes.
Get full access to this article
View all access options for this article.
References
1.
von AhsenN., MullerC., SerkeS.Important role of nondiagnostic blood loss and blunted erythropoietic response in the anemia of medical intensive care patients. Crit Care Med.1999; 27: 2630–9.
2.
CorwinH.L., ParsonnetK.C., GettingerA.RBC transfusion in the ICU: Is there a reason?Chest.1995; 108; 767–71.
3.
VincentJ.L., BaronJ.F., ReinhartK.Anemia and blood transfusion in critically ill patients. JAMA.2002; 288: 1499–507.
4.
CorwinH.L.Blood transfusions in the critically ill patient. Dis Mon.1999; 45: 409–26.
5.
LowL.L., HarringtonG.R., StoltzfusD.P.The effect of arterial lines on blood drawing practices and costs in ICUs. Chest.1995; 108: 216–19.
6.
Krafte-JacobsB.Anemia of critical illness and erythropoietin deficiency. Intensive Care Med.1997; 23: 137–8.
7.
RogiersP., ZhangH., LeemanM.Erythropoietin response is blunted in critically ill patients. Intensive Care Med.1997; 23: 159–62.
8.
Hobisch-HagenP., WiedermannF., MayrA.Blunted erythropoietin response to anemia in multiply traumatized patients. Crit Care Med.2001; 29: 743–7.
9.
van IperenC.E., GaillardCAJM, KraaijenhagenR.J.Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med.2000; 28: 2273–8.
10.
PatrutaS.L., HorlW.H.Iron and infection. Kidney Int.1999; 55(suppl 1): S125–30.
11.
TaylorR.W., ManganaroL., O'BrienJ.Impact of allogenic packed red blood cell transfusion on nosocomial infection rates in the critically ill patient. Crit Care Med.2002; 30: 2249–54.
12.
HebertP.C., WellsG., MarshallJ.Transfusion requirements in critical care: A pilot study. JAMA.1995; 274: 944.
13.
HebertP.C., WellsG., BlajchmanM.A.A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med.1999; 340: 409–17.
14.
HebertP.C., BlajchmanM.A., CookD.J.Do blood transfusions improve outcomes related to mechanical ventilation?Chest.2001; 119: 1850–7.
15.
WuW.C., RathoreS.S., WangY.Blood transfusions in elderly patients with acute myocardial infarction. N Engl J Med.2001; 345: 1230–6.
16.
BesarabA., BoltonW.K., BrowneJ.K.The effect of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med.1998; 339: 584–90.
17.
CorwinJ.L., GettingerA., PearlR.G.Efficacy of recombinant human erythropoietin in critically ill patients. JAMA.2002; 288: 2827–35.
18.
CarsonJ.L.Should patients in intensive care units receive erythropoietin?JAMA.2002; 288: 2884–6.
19.
AlbertM.S.Transfusion in elderly patients with myocardial infarction. N Engl J Med.2002; 346: 779–80.
20.
GoodnoughL.T., MonkT.G., AndrioleG.L.Erythropoietin therapy. N Engl J Med.1997; 336: 933–38.
21.
CorwinH.L., GettingerA., RodriguezR.M.Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized double-blind, placebo-controlled trial. Crit Care Med.1999; 27: 2346–50.
22.
D'AmbraM.N., GrayR.J., HillmanR.Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients. Ann Thorac Surg.1997; 64: 1686–93.
GershonS.K., LuksenburgH., CoteT.R.Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med.2002; 346: 1584–5.
25.
CasadevallN., NatafJ., VironB.Pure red-cell aplasia and antierythropoietin antibiodies in patients treated with recombinant erythropoietin. N Engl J Med.2002; 346: 469–75.
26.
PronovostP.J., AngusD.C., DormanT.Physician staffing patterns and clinical outcomes in critically ill patients. JAMA.2002; 288: 2151–62.
27.
DangD., JohantgenM.E., PronovostP.J.Postoperative complications: Does intensive care unit staff nursing make a difference?Heart Lung.2002; 31: 219–28.
28.
LeapeL.L., CullenD.J., ClappM.D.Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA.1999; 282: 267–70.
